Anti-OX40 antibodies
US10259882B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 6, 2016 |
| Grant date | Apr 16, 2019 |
| Priority date | — |
| Expiry date | Jan 19, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70578
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.